Anaphylaxis Market in 7MM is expected to witness a major change in the study period 2019-2032

"The Anaphylaxis market size shall enlarge due to the launch of upcoming therapies, advanced antiglaucoma medications, and patient-friendly dosage regimes"

The Anaphylaxis Market report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anaphylaxis market. A detailed review of the historical and forecasted Anaphylaxis market is included in the report, covering drug outreach in the 7MM.

Key highlights of the Anaphylaxis Market Report
• A study titled "The Epidemiology of Anaphylaxis", wherein the lifetime prevalence of anaphylaxis was estimated at 0.05-2% in the USA and approximately 3% in Europe. The study also mentioned that in UK, of patients presenting to paramedics and first aides estimated 0.2% of emergency cases due to anaphylaxis.
• Biphasic anaphylaxis is a recurrence of anaphylaxis after appropriate treatment. It happens with no additional exposure to the allergen and strikes after the patient has survived the initial attack.
• Anaphylaxis develops rapidly, usually reaching peak severity within 5 to 30 minutes, and may, rarely, last for several days.
• Approximately 1 in 5 admissions to hospitals in England due to allergies were for an anaphylactic reaction (4070 out of 20,318). This was an increase of 9.9% on the same period in the previous year. The NICE CG134 guideline reported an available UK estimate that about 1 in 1,333 of the population of England had experienced anaphylaxis at some point in their lives. However, a systematic review published in 2013 estimated that 1 in 300 people in Europe were affected by anaphylaxis at some point in their lives.
• The leading Anaphylaxis Companies are working include AstraZeneca, Aquestive Therapeutics, and many others
• Promising Anaphylaxis Pipeline Therapies include Acalabrutinib, AQST-108, AQST-109, and others

To know more about Anaphylaxis market companies & drugs of the report @ https://www.delveinsight.com/sample-request/anaphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Anaphylaxis Overview

Anaphylaxis is an acute, potentially life-threatening hypersensitivity reaction to a trigger such as an allergy and involving the release of mediators from mast cells, basophils and recruited inflammatory cells. Anaphylaxis usually develops rapidly, reaching peak severity within 5 to 30 minutes, and may, rarely, last for several days. The term anaphylaxis is often reserved to describe immunological, especially IgE-mediated reactions. A second term, non-allergic anaphylaxis, describes clinically identical reactions that are not immunologically mediated. Allergies to food, insect stings, medications and latex are most frequently associated with anaphylaxis.

Recent Developmental Activities in the Anaphylaxis Treatment Landscape

• In September 2020, ARS Pharmaceuticals announced that it has entered into an exclusive licensing agreement with Recordati for marketing rights in the European Union, Iceland, Liechtenstein, Norway, Switzerland, United Kingdom, Russia/CIS, Turkey, Middle East and French-speaking African countries, for ARS-1 (known as NeffyTM in the United States), an epinephrine nasal spray for Anaphylaxis.

Anaphylaxis Epidemiology Insights

The lifetime prevalence of anaphylaxis has been estimated at 1.6% to 5.1%. Medications and stinging insects are the leading triggers in adults, with foods and stinging insects the most frequently implicated triggers in children and adolescents. Food allergy impacts 8% to 11% of children and adults in the United States, while adverse drug reactions (ADRs) affect up to 10% of the population (and 20% of hospitalized patients), with hypersensitivity reactions (HSRs) accounting for 10% of all ADRs.

Anaphylaxis Epidemiology Segmentation in the 7MM

• Anaphylaxis Prevalent Population
• Anaphylaxis Diagnosed and Treatable Cases
• Anaphylaxis Trigger-specific Population

Anaphylaxis Market Insights

Anaphylaxis is variable and unpredictable. It may be mild and resolve spontaneously due to endogenous production of compensatory mediators or it may be severe and progress within minutes to respiratory or cardiovascular compromise and death. The treatment for anaphylaxis majorly includes the use of epinephrine to prevent the possible progression to life-threatening manifestations. When the patient is admitted at the hospital, they might receive glucocorticoid and antihistamines intravenously. These medications help to reduce inflammation in the air passages, improving your ability to breathe. They may also be given beta-agonists such as albuterol to make breathing easier and may also receive supplemental oxygen to help the body get the oxygen it needs.

Anaphylaxis Key Companies & Pipeline Therapies

• Pfizer: AQST-109
• Adamis Pharmaceuticals: AQST-108
• Aquestive Therapeutics: Symjepi
• Wyss Institute: EpiPen

Anaphylaxis Emerging Therapy Assessment

The pipeline of Anaphylaxis possess potential key player, such as Aquestive Therapeutics, Wyss Institute and others. The dynamics of Anaphylaxis market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment options. The launch of emerging therapies is expected during the forecast period of 2022-2032.

Explore details about the Anaphylaxis Market Research, Insight, and Forecast Report @ https://www.delveinsight.com/sample-request/anaphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Anaphylaxis Emerging Drugs

• AQST-108: Aquestive Therapeutics

AQST-108 is a "first of its kind" oral sublingual film formulation delivering systemic epinephrine using Aquestive's proprietary PharmFilm® technologies. It is currently in Phase I development for the treatment of allergic reactions (Type 1), including anaphylaxis. In August 2020, USFDA has granted Fast Track designation to AQST-108.

• NS-002: Nasus Pharma

NS-002 is an alpha and beta adrenergic receptor agonists. This Intransal Epinephrine formulation is in Phase II development for the treatment of anaphylactic shock.

Scope of the Anaphylaxis Market Research Report
• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period- 2022-2032
• Anaphylaxis Companies- AstraZeneca, Aquestive Therapeutics, and others.
• Anaphylaxis Pipeline Therapies- Acalabrutinib, AQST-108, AQST-109, and others
• Anaphylaxis Market Dynamics: Anaphylaxis Market Drivers and Barriers

Table of Content
1. Key Insights
2. Anaphylaxis Executive Summary
3. Competitive Intelligence Analysis
4. Anaphylaxis Market Overview at a Glance
5. Anaphylaxis Disease Background and Overview
6. Patient Journey
7. Anaphylaxis Epidemiology and Patient Population
8. Anaphylaxis Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Anaphylaxis Treatment
11. Anaphylaxis Marketed Products
12. Anaphylaxis Emerging Therapies
13. Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Anaphylaxis Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. Anaphylaxis Market Drivers
19. Anaphylaxis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Learn how new players' entries will transform the Anaphylaxis market dynamics in the coming years at Anaphylaxis Market Drivers and Barriers- https://www.delveinsight.com/report-store/anaphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.